Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

被引：0
|
作者：
Ondhia, U. [1 ]
Conter, H. [2 ]
Owen, S. [3 ]
Zhou, A. [4 ]
Nam, J. [1 ]
Singh, S. [4 ]
Abdulla, A. [5 ]
Chu, P. [5 ]
Felizzi, F. [5 ]
Sangha, R. [6 ]
机构：
[1] Hoffmann La Roche Ltd, Mississauga, ON, Canada
[2] William Osler Hlth Syst, Brampton, ON, Canada
[3] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[4] Cornerstone Res Grp Inc, Burlington, ON, Canada
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Cross Canc Inst, Edmonton, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
NSCLC; Immunotherapy; Cost-effectiveness;
D O I：
10.1016/j.jtho.2018.08.1724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.04-17
引用
收藏
页码：S928 / S928
页数：1
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN PORTUGAL
    Pinheiro, B.
    Silva Miguel, L.
    Alarcao, J.
    Paracha, N.
    Felizzi, F.
    Pereira, C.
    Borges, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S450 - S450
  • [2] Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)
    Ondhia, Umang
    Conter, H. J.
    Owen, Scott
    Zhou, Anna
    Nam, Julian
    Singh, Sumeet
    Abdulla, Ahmed
    Chu, Paula
    Felizzi, Federico
    Paracha, Noman
    Sanghag, Randeep
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (07) : 625 - 637
  • [3] A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS DOCETAXEL FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN BELGIUM
    Moeremans, K.
    Van Bellinghen, L.
    De Celle, T.
    Quintens, B.
    Paracha, N.
    [J]. VALUE IN HEALTH, 2018, 21 : S44 - S44
  • [4] Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer
    Pavlakis, N
    Mitchell, PL
    Slynes, G
    Aristides, M
    Davey, P
    Rajan, N
    Arora, B
    Liepa, AM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 549S - 549S
  • [5] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Hannah A. Blair
    [J]. Targeted Oncology, 2018, 13 : 399 - 407
  • [6] Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer
    Blair, Hannah A.
    [J]. TARGETED ONCOLOGY, 2018, 13 (03) : 399 - 407
  • [7] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [8] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Liu, Qiao
    Luo, Xia
    Peng, Liubao
    Yi, Lidan
    Wan, Xiaomin
    Zeng, Xiaohui
    Tan, Chongqing
    [J]. CLINICAL DRUG INVESTIGATION, 2020, 40 (02) : 129 - 137
  • [9] Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis
    Qiao Liu
    Xia Luo
    Liubao Peng
    Lidan Yi
    Xiaomin Wan
    Xiaohui Zeng
    Chongqing Tan
    [J]. Clinical Drug Investigation, 2020, 40 : 129 - 137
  • [10] COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB IN METASTATIC ALK plus NON-SMALL CELL LUNG CANCER (NSCLC)
    Montero, Alberto J.
    Lopes, Gilberto
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1211 - S1212
12345